Complement Inhibitors Suppress CARPA and CRS During Therapeutic Administration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Complement Activation-Related Pseudoallergy (CARPA) and Cytokine Release Syndrome (CRS) are significant issues during the administration of certain therapeutics, leading to severe systemic inflammatory reactions, and there is a need for effective methods to suppress these conditions.
Innovation Solution
Administering a composition comprising therapeutic agents capable of local or systemic activation of the complement system in combination with complement inhibitors, such as short-acting inhibitors that target enzymatic activities of complement proteins like C5, C6, C7, C9, factor D, and factor B, to reduce or eliminate complement-mediated responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic agents capable of activating the complement system are administered to treat disease, then therapeutic efficacy is improved, but Complement Activation-Related Pseudoallergy (CARPA) and Cytokine Release Syndrome (CRS) occur causing severe systemic inflammatory reactions
Solution Approach 1:
The patent introduces complement inhibitors (such as eculizumab, ravulizumab, or C3 inhibitors) as intermediary substances that selectively block the complement activation pathway. These inhibitors act as mediators between the therapeutic agent and the complement system, preventing harmful complement-mediated inflammatory responses while allowing the therapeutic agent to maintain its intended efficacy. The inhibitor binds to specific complement components (C5, C3) to prevent formation of the membrane attack complex and downstream inflammatory cascades.
Solution Approach 2:
The patent applies preliminary anti-action by administering complement inhibitors before or concurrently with the complement-activating therapeutic agent. This preemptive approach blocks the complement activation pathway in advance, preventing the development of CARPA and CRS symptoms before they can occur. The inhibitor is given prophylactically to neutralize potential harmful effects before the therapeutic agent triggers complement activation.
2Object-affected harmful factors
If complement inhibitors are administered to suppress CARPA and CRS, then safety is improved, but therapeutic agent efficacy may be reduced due to blocked complement activation
Solution Approach 1:
The patent applies partial action by using complement inhibitors that selectively block specific pathways or components of the complement system rather than completely suppressing all complement activity. For example, C5 inhibitors block only the terminal pathway while leaving upstream regulatory mechanisms intact. This partial inhibition is sufficient to prevent harmful CARPA and CRS reactions while preserving enough complement function to maintain therapeutic efficacy for conditions that require complement-mediated immunity.
Solution Approach 2:
The patent utilizes parameter changes by adjusting the timing, dosage, and duration of complement inhibitor administration to optimize the balance between safety and efficacy. The inhibitor dosage is titrated to achieve sufficient complement suppression to prevent CARPA/CRS while maintaining minimal complement activity for therapeutic benefit. Administration timing is optimized to provide protection during the critical window when the therapeutic agent is most likely to activate complement.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively reduces or eliminates symptoms associated with CARPA and CRS by inhibiting complement activation, as demonstrated by reduced cytokine responses and improved safety profiles in animal models and clinical settings.
Implementation Method 1
Complement components achieve their immune defensive functions by interacting in a series of intricate but precise enzymatic cleavage and membrane binding events. When stimulated by one of several triggers, proteases in the system cleave specific proteins to release cytokines and initiate an amplifying cascade of further cleavages.
Data Source
AI summary
Disclosed herein are methods and compositions for reducing or eliminating a complement-mediated response in a patient receiving treatment for a disease or disorder wherein one or more therapeutic agents is administered to the patient along with one or more complement inhibitors. Administration of the complement inhibitor along with the therapeutic agent results in a reduced or eliminated complement-mediated response, such as a reduction or elimination of symptoms associated with Complement Activation-Related Pseudoallergy (CARPA) or Cytokine Release Syndrome (CRS).